Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $470 | ― | 7.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $120→$140 | ― | 11.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $32 | ― | 16.70% | Reiterated | ||||
 | Expand Energy | BUY $122 | ― | -2.00% | Reiterated | Barclays Sticks to Its Buy Rating for Expand Energy (EXE) | |||
| Exxon Mobil | BUY $127 | ― | -2.00% | Reiterated | Barclays Keeps Their Buy Rating on Exxon Mobil (XOM) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $31 | ― | 16.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $165 | ― | 9.60% | Reiterated | ||||
| Murphy Oil | SELL $22 | ― | -2.00% | Reiterated | Barclays Sticks to Their Sell Rating for Murphy Oil (MUR) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $58 | ― | 16.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $105 | ― | 5.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $29→$30 | ― | 9.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $46→$55 | ― | 1.20% | Upgraded | ||||
 | Capricor Therapeutics | BUY $31 | ― | -9.80% | Initiated | Capricor Therapeutics initiated with a Buy at Roth Capital | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $14 | ― | 14.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $44 | ― | 5.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $56→$61.25 | ― | 5.40% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $10→$9 | ― | 3.90% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $331 | ― | 4.40% | Reiterated | ||||
| Kymera Therapeutics | BUY $55 | ― | -7.30% | Initiated | Kymera Therapeutics: Promising Growth in Biotechnology with Innovative Degrader Platform and Strategic Partnerships | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $58→$55 | ― | 7.90% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $14 | ― | 4.40% | Downgraded | ||||
| Resmed | BUY $280 | ― | -1.50% | Reiterated | Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109's Appeal | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $52.7 | ― | 26.30% | Reiterated | ||||
 | Prime Medicine, Inc. | BUY $10→$6 | ― | -6.40% | Reiterated | Prime Medicine price target lowered to $6 from $10 at Citizens JMP | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $92→$105 | ― | 20.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $100 | ― | 8.50% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $303 | ― | 4.70% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $5 | ― | 14.90% | Reiterated | ||||
Sondre SnersrudNordea Markets Not Ranked | Golden Ocean Group | HOLD $15.91 | ― | ― | Downgraded | Golden Ocean downgraded to Hold from Buy at Nordea | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $135→$110 | ― | 21.40% | Downgraded | ||||
 | ImmunityBio | BUY $4.25→$5 | ― | -21.80% | Upgraded | ImmunityBio upgraded to Overweight from Neutral at Piper Sandler | |||
| Richtech Robotics Inc. Class B | BUY $3.5 | ― | -20.00% | Reiterated | Analysts Offer Insights on NA Companies: Richtech Robotics Inc. Class B (NASDAQ: RR), Alto Neuroscience, Inc. (NYSE: ANRO) and Nano Nuclear Energy Inc. (NASDAQ: NNE) | |||
 | Trevi Therapeutics | BUY $24 | ― | -0.10% | Reiterated | Buy Rating for Trevi Therapeutics Driven by Promising Haduvio Trial Results and Strong Efficacy in RCC and IPF Cough | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $50 | ― | 16.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $150→$175 | ― | 10.40% | Reiterated | ||||
 | Agilysys | BUY $105 | ― | -2.70% | Reiterated | Agilysys Receives Buy Rating Amid Strong Performance and Growth Potential, Target Price Raised to $105 | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $350→$190 | ― | 13.70% | Downgraded | ||||
| Transcat | BUY $106 | ― | -20.00% | Reiterated | Transcat's Strong Financial Performance and Strategic Positioning Justify Buy Rating | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $17→$22 | ― | 12.80% | Upgraded | ||||
 | Vir Biotechnology | BUY $110→$15 | ― | -4.40% | Reiterated | Vir Biotechnology price target lowered to $15 from $110 at H.C. Wainwright | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $5.5 | ― | 10.90% | Initiated | ||||
| Alto Neuroscience, Inc. | BUY $10 | ― | -4.40% | Reiterated | Analysts Offer Insights on NA Companies: Richtech Robotics Inc. Class B (NASDAQ: RR), Alto Neuroscience, Inc. (NYSE: ANRO) and Nano Nuclear Energy Inc. (NASDAQ: NNE) | |||
| ATAI Life Sciences | BUY $10 | ― | -4.40% | Reiterated | ATAI Life Sciences: Positioned for Leadership in Scalable Psychedelic Psychiatry with Strong Financial Foundation and Promising Clinical Milestones | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $280→$286 | ― | 17.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $390→$415 | ― | 12.80% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $1.9 | ― | 6.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $134 | ― | 3.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $55 | ― | 0.20% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $11 | ― | 8.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $67→$73 | ― | 8.00% | Reiterated |
Rows:
